menu search

ACST / Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine

Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine
Acasti Pharma Inc's (NASDAQ: ACST) pharmacokinetic (PK) bridging study with IV GTX-104, its lead drug candidate for Subarachnoid Hemorrhage (SAH), met all its planned study endpoints.  The study's primary objective was to evaluate the relative bioavailability of IV GTX-104. Read More
Posted: May 18 2022, 11:28
Author Name: Benzinga
Views: 080397

ACST News  

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

By GlobeNewsWire
August 9, 2023

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company adva more_horizontal

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

By Seeking Alpha
February 14, 2023

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

Acasti Pharma Inc. (NASDAQ:ACST ) Q3 2023 Earnings Conference Call February 14, 2023 1:00 PM ET Company Representatives Jan D'Alvise - President, Chie more_horizontal

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

By Seeking Alpha
November 14, 2022

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

Acasti Pharma Inc. (NASDAQ:ACST ) Q2 2023 Earnings Conference Call November 14, 2022 1:00 PM ET Company Participants Robert Blum - Lytham Partners, IR more_horizontal

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

By GlobeNewsWire
June 16, 2022

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

Call to be held on Tuesday, June 21st at 1:00 PM Eastern Time Call to be held on Tuesday, June 21st at 1:00 PM Eastern Time more_horizontal

Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine

By Benzinga
May 18, 2022

Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine

Acasti Pharma Inc's (NASDAQ: ACST) pharmacokinetic (PK) bridging study with IV GTX-104, its lead drug candidate for Subarachnoid Hemorrhage (SAH), m more_horizontal

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

By Seeking Alpha
February 14, 2022

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript more_horizontal

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

By Seeking Alpha
February 14, 2022

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript more_horizontal

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

By Seeking Alpha
February 14, 2022

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript

Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q3 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: